“Altering the affinity of either a small set of CD3-binding antibodies, or an antibody such as SP34-2, is a frequently used strategy to reduce risk of cytokine release syndrome by TCEs.

BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a ...

The compound presents a stronger binding affinity for EGFR than for CD3 to avoid the development of cytokine release syndrome, which is a safety issue common in CD3-based bispecific antibodies.

More than 90% of patients with relapsed or refractory multiple myeloma who received the two highest doses of REGN5459 responded to treatment with the investigational bispecific antibody, results ...

Kuick Research Report Highlights Ongoing Clinical Developments, Antibodies Sales & Market TrendsDelhi, March 21, 2023 (GLOBE NEWSWIRE) -- Antibodies have transformed cancer treatment because of ...

NANJING, China, April 15, 2025 /PRNewswire/ -- ProBio, a global leader in the antibody discovery and development, is pleased to announce its upcoming poster presentation at the American ...

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials. Cancer ...

“ Altering the affinity of either a small set of CD3-binding antibodies, or an antibody such as SP34-2, is a frequently used strategy to reduce risk of cytokine release syndrome by TCEs.

ProBio, a global leader in the antibody discovery and development, is pleased to announce its upcoming poster presentation at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, ...